Opdivo, Bristol-Myers Squibb

FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors,
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why I'm bullish on BMY heading into 2025.
Ipilimumab + nivolumab by Bristol-Myers Squibb for Dedifferentiated Liposarcoma: Likelihood of Approval
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Dedifferentiated Liposarcoma.
US FDA approves injectable form of Bristol Myers' Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors,
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications: Princeton, New Jersey Monday, December 30, 2024,
Bristol Myers Squibb Stock In Focus After FDA Approves Cancer Drug: Retail Sentiment Brightens
Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an injectable version of the pharmaceutical major’s cancer drug Opdivo. Opdivo is reportedly part of PD-1 inhibitors class of drugs,
Bristol-Myers gets FDA okay for injectable Opdivo
The FDA has reportedly approved an injectable formulation of Bristol-Myers Squibb's (NYSE:BMY) oncology drug Opdivo. Previously, the PD-1 inhibitor drug was only available through IV infusion. The injectable formulation,
pharmaphorum10h
Opdivo's subcutaneous PD-1 inhibitor cleared in US
Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...
FDA approves BMS’ Opdivo Qvantig for solid tumour indications
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...
Contract Pharma4h
FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology
Becomes the first subcutaneously administered PD-1 inhibitor.
BioWorld2h
Progress in cancer research, even the toughest types
Among the most profound results presented at the 2024 European Society for Medical Oncology (ESMO) Congress were the 10-year ...
devdiscourse6h
New Developments in Health: Drug Approvals and Market Reactions
The FDA has approved an injectable version of the cancer drug Opdivo by Bristol Myers Squibb. Meanwhile, Axsome's Alzheimer's ...
Business Insider12h
Halozyme Says FDA Approved Bristol Myers's Opdivo Qvantig With ENHANZE For Subcutaneous Use
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) Monday said that the Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Opdivo Qvantig co-formulated with Halozyme's ENHANZE drug ...
Hosted on MSN6d
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...
devdiscourse1d
Breakthroughs and Battles in Health: New Approvals, Lawsuits, and Discoveries
Recent health developments include the FDA's approval of an injectable version of Bristol Myers Squibb's cancer drug Opdivo.